De-risk & accelerate the drug development process for gene therapy

Abstract

Kim Watanabe, PhD is the General Manager, Site Head for Patheon Translational Services. As part of the pharma services contract development and manufacturing organizational arm of Thermo Fisher Scientific, she leads the newly launched business that provides discovery stage, clinically bound clients with molecular biology, viral vector, and cell therapy services for in vivo gene therapy and ex vivo modified cell-based therapy research applications. Since joining Thermo Fisher Scientific in 2016, she has held multiple roles with increasing responsibility in product management and business integration and development. Prior to her current tenure, she was a Senior. Global Product Manager at Irvine Scientific (now Fujifilm Irvine Scientific), where she focused on cell culture products to support cell therapy applications. She was a stem cell research scientist at ScienCell Research Laboratories. Dr. Watanabe was a postdoctoral scholar at the University of California, San Diego, and received her doctoral degree in microbiology from the University of Virginia, and her BSc in cell and structural biology from the University of Illinois at Urbana-Champaign.